First-line Helicobacter pylori Eradication Rate of the 10-day Hybrid Therapy
- Author:
Jeong Hun PARK
1
;
Dongwoo KIM
;
Jung Wan CHOE
;
Seung Young KIM
;
Sung Woo JUNG
;
Jong Jin HYUN
;
Young Kul JUNG
;
Ja Seol KOO
;
Hyung Joon YIM
;
Sang Woo LEE
Author Information
- Publication Type:Original Article
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020;20(4):300-305
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background/Aims:To improve the eradication rate of a first-line therapy for Helicobacter pylori infection, alternate regimens such as sequential, concomitant, and hybrid therapies have been tried. The aim of this study was to evaluate the eradication rate of the 10-day hybrid therapy as a first-line therapy.
Materials and Methods:This retrospective study enrolled 124 patients from the Korea University Ansan Hospital between April 2016 and December 2019. The 10-day hybrid therapy comprised 5 days of dual therapy (proton pump inhibitor [PPI] standard dose and amoxicillin 1 g, twice daily) followed by 5 days of quadruple therapy (PPI, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, twice daily). We compared the 10-day hybrid therapy with the 10-day concomitant therapy comprising PPI, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, twice daily. Eradication was assessed by a 13C-urea breath test or gastroscopic biopsy at least 4 weeks after treatment completion.
Results:The eradication rates of the 10-day hybrid and concomitant therapies were 74.2% (46/62) and 67.7% (42/62), respectively, in the intention-to-treat (ITT) analysis and 88.5% (46/52) and 82.4% (42/51), respectively, in the per-protocol (PP) analysis. There was no significant difference in the eradication rates between the two groups in the ITT (P=0.429) and PP analysis (P=0.380). Adverse events developed in 75.0% and 70.6% of patients in the hybrid and concomitant groups, respectively, but there was no significant difference (P=0.615).
Conclusions:The 10-day hybrid therapy can be an option for a first-line therapy of Helicobacter pylori infection.
